Literature DB >> 20492494

Impaired cerebral autoregulation in primary biliary cirrhosis: implications for the pathogenesis of cognitive decline.

Kieren G Hollingsworth1, David E J Jones, Roy Taylor, James Frith, Andrew M Blamire, Julia L Newton.   

Abstract

BACKGROUND: Cognitive impairment is recognised in the early stages of primary biliary cirrhosis (PBC). AIMS: To determine the mechanisms that underlie the cognitive dysfunction that can occur in early-stage PBC, with a particular focus on the role of autonomic dysfunction and altered cerebral autoregulation. PATIENTS: Early-stage PBC patients, and age- and sex-matched controls. INTERVENTIONS AND MAIN OUTCOME MEASURES: Brain magnetic resonance imaging to determine the relationship between structural brain abnormalities (T(2)) and cerebral vasculature responsiveness assessed using the Valsalva manoeuvre. Dynamic assessment of cerebral vascular flow using transcranial Doppler was also performed in PBC subjects to derive the pulsatility index (a marker of cerebral resistance) and the autoregulatory slope index [ASI; ratio between the cerebral blood flow velocity and blood pressure (BP)].
RESULTS: Cerebral resistance was increased (P=0.04), and cerebral autoregulation in response to the Valsalva was significantly impaired in the PBC group with markedly lower mean ASI values compared with the controls (7.8+/-7.0 vs -8.5+/-8.4; P=0.002). All controls had normal cerebral autoregulation compared with only 20% of the PBC group. Indicators of sympathetic failure (BP change between Valsalva phases III-IV and low-frequency heart rate variability) correlated with increasing globus pallidus (GP) T(2) values (P<0.05), beyond the effect of age.
CONCLUSION: This study demonstrates the presence of increased cerebral vascular resistance and abnormal cerebral autoregulation in PBC patients, and identifies a potentially important association between the degree of abnormality in structural changes in the GP. These findings suggest that organic brain injury in PBC is directly related to autonomic dysfunction.

Entities:  

Mesh:

Year:  2010        PMID: 20492494     DOI: 10.1111/j.1478-3231.2010.02259.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  5 in total

Review 1.  Novel therapeutic targets in primary biliary cirrhosis.

Authors:  Jessica K Dyson; Gideon M Hirschfield; David H Adams; Ulrich Beuers; Derek A Mann; Keith D Lindor; David E J Jones
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-02-03       Impact factor: 46.802

Review 2.  Shared symptoms and putative biological mechanisms in chronic liver disease: implications for biobehavioral research.

Authors:  Victoria Menzies; Nancy Jallo; Patricia Kinser; Jo Lynne W Robins; Kyungeh An; Carolyn Driscoll; Angela Starkweather; Jasmohan S Bajaj; Debra E Lyon
Journal:  Biol Res Nurs       Date:  2014-07-18       Impact factor: 2.522

3.  Fatigue in primary sclerosing cholangitis is associated with sympathetic over-activity and increased cardiac output.

Authors:  Jessica K Dyson; Ahmed M Elsharkawy; Christopher A Lamb; Ahmad Al-Rifai; Julia L Newton; David E Jones; Mark Hudson
Journal:  Liver Int       Date:  2014-12-04       Impact factor: 5.828

4.  Hepatic Encephalopathy-Associated Cerebral Vasculopathy in Acute-on-Chronic Liver Failure: Alterations on Endothelial Factor Release and Influence on Cerebrovascular Function.

Authors:  Laura Caracuel; Esther Sastre; María Callejo; Raquel Rodrigues-Díez; Ana B García-Redondo; Isabel Prieto; Carlos Nieto; Mercedes Salaices; Ma Ángeles Aller; Jaime Arias; Javier Blanco-Rivero
Journal:  Front Physiol       Date:  2020-11-20       Impact factor: 4.566

5.  The impact of liver transplantation on the phenotype of primary biliary cirrhosis patients in the UK-PBC cohort.

Authors:  Greta Pells; George F Mells; Marco Carbone; Julia L Newton; Andrew J Bathgate; Andrew K Burroughs; Michael A Heneghan; James M Neuberger; Darren B Day; Samantha J Ducker; Richard N Sandford; Graeme J Alexander; David E J Jones
Journal:  J Hepatol       Date:  2013-03-04       Impact factor: 25.083

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.